-Super Speed of Only Nine Months

Maryland-based biotechnology leader, Elixirgen Scientific, Inc., launches Alzheimer’s Disease Panel, strengthening their commitment to quality and innovation in disease research and drug discovery.

Dr. Torrejon, the original founder of Humonix, replaces Kimberly Southern

Pace® Life Sciences continues to make investments to broaden their comprehensive suite of oral solid dose development offerings.

New innovative clinical services to help pharmaceutical and biotech companies improve patient recruitment, reduce the risk of adverse reactions, and refine the drug development process.

Complimentary Workshop to Provide Expert Insight and Strategies for Regulatory Affairs Specialists, Pharmaceutical Enthusiasts and Drug Developers

Kivo’s expanded platform brings compliant collaboration and intelligent process automation to emerging Regulatory, Clinical and Quality teams.

Specialty pharmaceutical research company’s new retinal vascular dysfunction model can have a major impact on research and development of new drugs for retinal vascular diseases.

Specialty pharmaceutical research company celebrates the launch of a new service offering and with it, a brand refresh.

Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.

Pharma industry veterans focus on asset value creation for sponsors

The SYNGAP1 Gene: Seeking Treatments and the Genetic Link to Related Neurological Disorders

As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.

First joint research project between Sanofi and the BioMed X Institute, co-creation of a next-generation virtual patient engine for clinical translation of drug candidates

As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms

CaaMTech will help carry on Dr. Alexander Shulgin's legacy by developing ASRI's novel compounds

PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, showcases the utility and performance of its FibroNest continuous score for the quantification of the severity of fibrosis and treatment effects of NASH therapies at the 2022 International Liver Conference.

The Tribun Health executive team is growing with the creation of a VP Pharma position to develop the expanding pharmaceutical business.

Charles River will license Hera's SRG rat (OncoRat), the first highly immunocompromised rat model

Dr. Discordia brings over 30 years of pharmaceutical industry experience to CaaMTech

Turnkey research facility in The East Side neighborhood expands national network

Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cannabis Business Times' and 'Hemp Grower'

Turnkey research facilities expand national network, opens new market

The sale will accelerate the development of Gb Sciences' proprietary Parkinson's disease and COVID-related Cytokine-Release Syndrome therapies

Scientists will assess the potential of psychedelic compounds for treating addiction

New digital pathology, quantitative image analysis and quantitative AI method for liver tissues is presented for the continuous assessment of the histological phenotype(s) of fibrosis, including severity and regression of fibrosis in Human in-vitro 3D NASH Spheroid models, NASH rodent models, Clinical Phase2b NASH Studies at the Liver Meeting Digital Experience™ 2021

Woven Science's El Puente foundation is pleased to release for public comment its policy paper and corporate social responsibility initiative for psychedelic pharmaceutical companies to engage with indigenous peoples using psychedelic botanicals in traditional practice. This paper explores how public policymakers in collaboration with companies can offer indigenous communities influence over product development, consumer preferences, profit sharing, and public perception.

The investment provides CaaMTech with capital to advance compounds from its library into clinical trials

GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain inspired by a family of pepper plants used in traditional medicines around the world.

Woven Science is the first company to take a holistic approach to mental wellbeing through psychedelic models of care, while putting a system of reciprocity towards indigenous communities at the core of its business.

The in-vitro studies performed in Glauconix's co-culture 3D conventional human outflow model confirm efficacy

CaaMTech's first of over one hundred patent applications is nearing the finish line

New eISF Standard Reference Model Promises to Strengthen Collaboration Among Stakeholders in Clinical Trial Life cycle.

Surge of Research Organizations Investing in Florence Shows New Wave of Site Leadership in Streamlining Study Operations

Fulcrum Equity Partners leads investment round, along with Bee Partners and Atrium Health, to support Florence creating a new type of research network that speeds progress.